Becton, Dickinson And Company (BDX)

$234.18

-1.32

(-0.56%)▲

Market is closed - opens 7 PM, 16 Sep 2024

Performance

  • $233.86
    $237.50
    $234.18
    downward going graph

    0.14%

    Downside

    Day's Volatility :1.53%

    Upside

    1.4%

    downward going graph
  • $218.75
    $269.52
    $234.18
    downward going graph

    6.59%

    Downside

    52 Weeks Volatility :18.84%

    Upside

    13.11%

    downward going graph

Returns

PeriodBecton, Dickinson And CompanySector (Health Care)S&P500
3 Months
0.19%
7.0%
3.6%
6 Months
-1.26%
7.0%
9.2%
1 Year
-11.5%
17.2%
24.9%
3 Years
-10.09%
18.0%
26.6%

Highlights

Market Capitalization
67.7B
Book Value
$89.5
Dividend Share
3.76
Dividend Yield
1.61%
Earnings Per Share (EPS)
4.99
PE Ratio
46.93
PEG Ratio
1.09
Wall Street Target Price
273.43
Profit Margin
7.13%
Operating Margin TTM
15.13%
Return On Assets TTM
3.25%
Return On Equity TTM
5.63%
Revenue TTM
19.8B
Revenue Per Share TTM
68.37
Quarterly Revenue Growth YOY
2.3%
Gross Profit TTM
8.8B
EBITDA
5.1B
Diluted Eps TTM
4.99
Quarterly Earnings Growth YOY
0.24
EPS Estimate Current Year
13.11
EPS Estimate Next Year
14.26
EPS Estimate Current Quarter
3.31
EPS Estimate Next Quarter
3.89

Analyst Recommendation

Buy
    70%Buy
    30%Hold
    0
    0%Sell
Based on 20 Wall street analysts offering stock ratings for Becton, Dickinson And Company(by analysts ranked 0 to 5 stars)
Based on 20 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
15
15
Hold
6
5
5
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 16.76%

Current $234.18
Target $273.43

Company Financials

FY18Y/Y Change
Revenue
16.0B
↑ 32.17%
Net Income
311.0M
↓ 71.73%
Net Profit Margin
1.95%
↓ 7.15%
FY19Y/Y Change
Revenue
17.3B
↑ 8.18%
Net Income
1.2B
↑ 292.28%
Net Profit Margin
7.06%
↑ 5.11%
FY20Y/Y Change
Revenue
17.1B
↓ 1.0%
Net Income
874.0M
↓ 28.36%
Net Profit Margin
5.11%
↓ 1.95%
FY21Y/Y Change
Revenue
20.2B
↑ 18.29%
Net Income
2.1B
↑ 139.36%
Net Profit Margin
10.33%
↑ 5.22%
FY22Y/Y Change
Revenue
18.9B
↓ 6.81%
Net Income
1.8B
↓ 14.96%
Net Profit Margin
9.43%
↓ 0.9%
FY23Y/Y Change
Revenue
19.4B
↑ 2.66%
Net Income
1.5B
↓ 16.58%
Net Profit Margin
7.66%
↓ 1.77%
Q1 FY23Q/Q Change
Revenue
4.8B
↑ 5.12%
Net Income
460.0M
↓ 9.63%
Net Profit Margin
9.54%
↓ 1.56%
Q2 FY23Q/Q Change
Revenue
4.9B
↑ 1.18%
Net Income
407.0M
↓ 11.52%
Net Profit Margin
8.34%
↓ 1.2%
Q3 FY23Q/Q Change
Revenue
5.1B
↑ 4.28%
Net Income
108.0M
↓ 73.46%
Net Profit Margin
2.12%
↓ 6.22%
Q4 FY23Q/Q Change
Revenue
4.7B
↓ 7.49%
Net Income
281.0M
↑ 160.19%
Net Profit Margin
5.97%
↑ 3.85%
Q1 FY24Q/Q Change
Revenue
5.0B
↑ 7.2%
Net Income
537.0M
↑ 91.1%
Net Profit Margin
10.64%
↑ 4.67%
Q2 FY24Q/Q Change
Revenue
5.0B
↓ 1.09%
Net Income
487.0M
↓ 9.31%
Net Profit Margin
9.76%
↓ 0.88%
FY18Y/Y Change
Total Assets
53.9B
↑ 42.85%
Total Liabilities
32.9B
↑ 32.78%
FY19Y/Y Change
Total Assets
51.8B
↓ 3.83%
Total Liabilities
30.7B
↓ 6.82%
FY20Y/Y Change
Total Assets
54.0B
↑ 4.19%
Total Liabilities
30.2B
↓ 1.4%
FY21Y/Y Change
Total Assets
53.9B
↓ 0.27%
Total Liabilities
30.2B
↓ 0.16%
FY22Y/Y Change
Total Assets
52.9B
↓ 1.73%
Total Liabilities
27.6B
↓ 8.47%
FY23Y/Y Change
Total Assets
52.8B
↓ 0.29%
Total Liabilities
27.0B
↓ 2.35%
Q1 FY23Q/Q Change
Total Assets
54.4B
↑ 2.38%
Total Liabilities
28.7B
↑ 3.9%
Q2 FY23Q/Q Change
Total Assets
53.0B
↓ 2.53%
Total Liabilities
27.1B
↓ 5.66%
Q3 FY23Q/Q Change
Total Assets
52.8B
↓ 0.45%
Total Liabilities
27.0B
↓ 0.35%
Q4 FY23Q/Q Change
Total Assets
52.3B
↓ 0.96%
Total Liabilities
26.9B
↓ 0.16%
Q1 FY24Q/Q Change
Total Assets
54.2B
↑ 3.6%
Total Liabilities
28.5B
↑ 5.82%
Q2 FY24Q/Q Change
Total Assets
55.6B
↑ 2.63%
Total Liabilities
29.7B
↑ 4.23%
FY18Y/Y Change
Operating Cash Flow
2.9B
↑ 12.35%
Investing Cash Flow
-15.8B
↑ 1692.64%
Financing Cash Flow
-57.0M
↓ 100.52%
FY19Y/Y Change
Operating Cash Flow
3.3B
↑ 16.23%
Investing Cash Flow
-741.0M
↓ 95.32%
Financing Cash Flow
-3.2B
↑ 5556.14%
FY20Y/Y Change
Operating Cash Flow
3.5B
↑ 6.28%
Investing Cash Flow
-1.2B
↑ 66.26%
Financing Cash Flow
22.0M
↓ 100.68%
FY21Y/Y Change
Operating Cash Flow
4.6B
↑ 31.31%
Investing Cash Flow
-1.9B
↑ 52.6%
Financing Cash Flow
-3.3B
↓ 15127.27%
FY22Y/Y Change
Operating Cash Flow
2.6B
↓ 43.34%
Investing Cash Flow
-3.2B
↑ 71.28%
Financing Cash Flow
-591.0M
↓ 82.12%
FY23Y/Y Change
Operating Cash Flow
3.0B
↑ 13.52%
Investing Cash Flow
-716.0M
↓ 77.76%
Financing Cash Flow
-2.0B
↑ 231.13%
Q1 FY23Q/Q Change
Operating Cash Flow
184.0M
↓ 54.0%
Investing Cash Flow
-233.0M
↓ 19.93%
Financing Cash Flow
1.4B
↓ 356.47%
Q2 FY23Q/Q Change
Operating Cash Flow
1.1B
↑ 486.96%
Investing Cash Flow
-329.0M
↑ 41.2%
Financing Cash Flow
-1.8B
↓ 231.16%
Q3 FY23Q/Q Change
Operating Cash Flow
1.3B
↑ 22.69%
Investing Cash Flow
-716.0M
↑ 117.63%
Financing Cash Flow
-998.0M
↓ 44.34%

Technicals Summary

Sell

Neutral

Buy

Becton, Dickinson And Company is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Becton, Dickinson And Company
Becton, Dickinson And Company
0.04%
-1.26%
-11.5%
-10.09%
-9.49%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
3.96%
27.46%
61.28%
41.44%
180.65%
Resmed Inc.
Resmed Inc.
12.02%
29.82%
68.61%
-14.83%
90.44%
Alcon Ag
Alcon Ag
5.22%
14.64%
20.33%
13.95%
65.66%
Cooper Companies Inc., The
Cooper Companies Inc., The
20.9%
8.9%
-67.5%
0.15%
45.87%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Becton, Dickinson And Company
Becton, Dickinson And Company
46.93
46.93
1.09
13.11
0.06
0.03
0.02
89.5
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
84.02
84.02
4.21
6.65
0.16
0.08
NA
41.4
Resmed Inc.
Resmed Inc.
35.97
35.97
2.09
7.71
0.23
0.13
0.01
33.11
Alcon Ag
Alcon Ag
45.39
45.39
3.71
3.05
0.05
0.03
0.0
42.35
Cooper Companies Inc., The
Cooper Companies Inc., The
61.41
61.41
11.19
3.66
0.05
0.03
NA
39.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Becton, Dickinson And Company
Becton, Dickinson And Company
Buy
$67.7B
-9.49%
46.93
7.13%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
Buy
$174.1B
180.65%
84.02
27.65%
Resmed Inc.
Resmed Inc.
Buy
$36.6B
90.44%
35.97
21.79%
Alcon Ag
Alcon Ag
Buy
$49.7B
65.66%
45.39
11.44%
Cooper Companies Inc., The
Cooper Companies Inc., The
Buy
$22.0B
45.87%
61.41
9.45%

Insights on Becton, Dickinson And Company

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 5.04B → 4.99B (in $), with an average decrease of 1.1% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 537.0M → 487.0M (in $), with an average decrease of 9.3% per quarter

  • Vs RMD

    In the last 1 year, Resmed Inc. has given 68.6% return, outperforming this stock by 80.1%

Institutional Holdings

  • Vanguard Group Inc

    9.10%

  • BlackRock Inc

    7.70%

  • State Street Corp

    4.79%

  • T. Rowe Price Associates, Inc.

    3.72%

  • Morgan Stanley - Brokerage Accounts

    3.71%

  • T. Rowe Price Investment Management,Inc.

    2.68%

Corporate Announcements

  • Becton, Dickinson And Company Dividends March,2024

    In the quarter ending March,2024. Becton, Dickinson And Company has declared dividend of $0.95

    Read More

Company Information

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, and others.

Organization
Becton, Dickinson And Company
Employees
70000
CEO
Mr. Thomas E. Polen Jr.
Industry
Health Technology

Discover More

FAQs